A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 867-872

  Kawanami, Takako ^a   Takiguchi, Soichi ^a   Ikeda, Noriko ^b   Funakoshi, Akihiro ^c  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Apoptosis; Chemoresistance; Gemcitabine resistance; Metformin; Pancreatic cancer; R1507

Indexed keywords

GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MONOCLONAL ANTIBODY; R 1507; SOMATOMEDIN C RECEPTOR; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; METFORMIN; PANCREATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84856287736     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1597     Document Type: Article

References (30)

1. Kleeff J, Michalski C, Friess H and Buchler MW: Pancreatic cancer: from bench to 5-year survival. Pancreas 33: 111-118, 2006. (Pubitemid 44174558)
2. Ueno H, Kiyosawa K and Kaniwa N: Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer 97: 145-151, 2007. (Pubitemid 47057479)
3. Reni M, Cereda S and Galli L: PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen. Cancer Lett 256: 25-28, 2007. (Pubitemid 47334967)
4. Kurzrock R, Patnaik A, Aisner J, et al: A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16: 2458-2465, 2010.
5. Gong Y, Yao E, Shen R, et al: High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 4: e7273, 2009.
6. Kolb EA, Kamara D, Zhang W, et al: R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer 55: 67-75, 2010.
7. Funakoshi A, Kawanami T and Takiguchi S: Anti-tumor effect of the insulin-like growth factor (IGF)-1 receptor (IGF-1R) on human pancreatic cancer cells in both in vitro and in vivo studies. Suizo (In press).
8. Kisfalvi K, Eibl G, Sinnett-Smith J and Rozengurt E: Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69: 6539-6545, 2009.
9. Jalving M, Gietema JA, Lefrandt JD, et al: Metformin: taking away the candy for cancer? Eur J Cancer 46: 2369-2380, 2010.
10. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF and Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86: 886-892, 2002. (Pubitemid 34271023)
11. Kami K, Doi R, Koizumi M, et al: Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 136: 443-448, 2004. (Pubitemid 39037686)
12. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A and Shimosegawa T: Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92: 271-278, 2001. (Pubitemid 32664432)
13. Li F: Survivin study: what is the next wave? J Cell Physiol 197: 8-29, 2003.
14. Kim KW, Mutter RW, Willey CD, et al: Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys 67: 1519-1525, 2007. (Pubitemid 46467182)
15. Asanuma K, Kobayashi D, Furuya D, Tsuji N, Yagihashi A and Watanabe N: A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 93: 1057-1062, 2002. (Pubitemid 35154273)
16. Mesri M, Wall NR, Li J, Kim RW and Altieri DC: Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108: 981-990, 2001. (Pubitemid 32946072)
17. Pennati M, Binda M, Colella G, et al: Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120: 648-654, 2003. (Pubitemid 36344009)
18. Mufti AR, Burstein E and Duckett CS: XIAP: cell death regulation meets copper homeostasis. Arch Biochem Biophys 463: 168-174, 2007. (Pubitemid 47030333)
19. Iwamura T, Katsuki T and Ide K: Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res 78: 54-62, 1987. (Pubitemid 17037867)
20. Yunis AA, Arimura GK and Russin DJ: Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19: 128-135, 1977. (Pubitemid 8016933)
21. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA and Tsao MS: Long term culture and immortalization of epithelial cells from normal adult human pancreatic ducts by transfection with the E6E7 gene of human papilloma virus 16. Am J Pathol 148: 1763-1770, 1996. (Pubitemid 26171674)
22. Ouyang H, Mou LJ, Luk C, Liu N, Squire J and Tsao MS: Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157: 1623-1631, 2000.
23. Spandidos A, Wang X, Wang H and Seed B: PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res 38: D792-D799, 2010.
24. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
25. Park JK, Ryu JK, Lee JK, et al: Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas 33: 397-402, 2006. (Pubitemid 44690731)
26. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928, 2008.
27. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
28. Nakahara T, Takeuchi M, Kinoyama I, et al: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67: 8014-8021, 2007. (Pubitemid 47395135)
29. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P and Patel BK: Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 10: 221-232, 2011.
30. Schimmer AD, Dalili S, Batey RA and Riedl SJ: Targeting XIAP for the treatment of malignancy. Cell Death Differ 13: 179-188, 2006. (Pubitemid 43102202)